Telat KELES, Tahir DURMAZ, Huseyin AYHAN, Bilge Duran KARADUMAN, Engin BOZKURT

An update of dual antiplatelet therapy

Since platelet activation and aggregation play a major role in thrombus formation in lumen of coronary arteries, they constitute a main target in treatment of stable ischemic heart disease and acute coronary syndromes. Antiplatelet therapy should be commenced as early as possible within the current indications in order to reduce the risk of both acute ischemic complications and recurrent atherothrombotic events. Platelet functions can be inhibited by three classes of drugs having different mechanisms of action, namely acetylsalicylic acid, P2Y12 inhibitors, and glycoprotein IIb/IIIa antagonists. Dual antiplatelet therapy (acetylsalicylic acid and P2Y12 inhibitors) have recently been a hot topic of research with the advent of stents in recent years. Multiple regimens of antiplatelet and anticoagulation therapy have been used in the past in patients undergoing percutaneous coronary intervention. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation is unclear. Many clinicians have pushed for prolonged dual antiplatelet therapy — beyond 12 months — on the assumption that extended therapy reduces recurrentcardiovascular events. Despite the established guidelines, there is not a clear consensus about how to manage antiplatelet therapy. New antiplatelet agents have been developed for patients at high risk of thrombosis. Their benefits in terms of mortality and major cardiovascular events have been demonstrated, but some concerns remain regarding the possible increase in bleeding.The aim of this review was to summarize the current literature containing the potential solutions to problems related to indications and duration of dual antiplatelet therapy and its interaction with other medications.

PDF

___

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation. 2008;118 (1):815-6.
Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pumpinhibiting drugs omeprazole, esemeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32 (8):821-7.
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointesti-nal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Consensus Documents. Circulation 2008;118 (3):1894-909.
Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. WOEST study investigators. Use of clopidogrel with or without ASA in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;30;381 (9872):1107-15.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
Hermosillo AJ, Spinler SA. Aspirin clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother 2008;42 (6):790-805.
Helft G, Le Feuvre C, Georges JL, Carrie D, Leclercq F, Eltchaninoff H, et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013;21;14:56.
Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009;157(4):620–4.e2.
Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapyin subjects undergoing percutaneous coronary intervention with either drugeluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160 (6):1035–41,1041.E1.
Collet JP, Cayla G, Cuisset T, Elhadad S, Range G, Vicaut E, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of ASA and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011;161 (1):5–12.E5.
Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drugeluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33 (24):3078–87.
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho Rv, et al. OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;18;310 (23):2510-22.
Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60 (15):1340–8.
Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;24;125(3):505–13.
Van De Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent STsegment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909–45.
Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28 (13):1598– 660.
Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26 (8):804–47.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013;4;368 (14):1303-13.
The TRACER Executive and Steering Committees The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: Study design and rationale. Am Heart J. 2009;158 (3):327–34.
Collet JP, Cayla G, Cuisset T, Elhadad S, Rangé G, Vicaut E, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of ASA and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J. 2011;161(1):5-12.e5.
Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109 (2):166-71.
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (4): 354-62.
Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373 (9660): 309- 17.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26 (8): 1895-900.
Breet N, van Werkum J, Bouman H, Kelder J, Ruven H, Bal E, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303 (8):754– 762.
Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51 (20): 1925–1934.
Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27 (20):2420–2425.
Aalbers J. Prasugrel study addresses timing of thienopyridine loading dose in NSTEMI patients pre-PCI (the ACCOAST study). Cardiovasc J Afr. 2011 MayJun;22 (3):168.
Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med 2009;361 (24): 2330–41.
Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition in patients undergoing percutaneous coronary intervention (CHAMPION-PCI) trial. J Thromb Thrombolysis 2012 Jul;34 (1):44-55.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361 (11):1045–57.
S. Cannon C, Harrington R, James S, Ardissino D, Becker R, Emanuelsson H, et al. the PLATelet inhibition and patient Outcomes (PLATO) investigators. Ticagrelor compared with clopidogrel in acute coronary syndromes patients with a planned invasive strategy (PLATO): a randomised double-blind study. Lancet 2010;375 (9711):283–93.
Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;6;50(19):1844-51.
Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;16;121(10):1188-99.
Storey RF, Bliden K, Patil SB, Karunakaran A, Ecob R, Butler K, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET Study. J Am Coll Cardiol 2010;56 (3):185–93.
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al.; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367 (14):1297-309.
Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013;29(11):1334-45.
2012 Writing Committee Members, Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/nonST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2012;126 (7):875-910.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. TRITON–TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357 (20):2001-15.
Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011;106 (2):219-26.
Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;28;111(25):3366-73.
Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-ofcare assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29 (8):992-1000.
Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001). Circulation 2006;113 (7):166-286.
Weiss HJ. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med 1975;293 (11):531–41.
The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and ASA in acute coronary syndromes. N Engl J Med 2010;363 (10) :930–42.
Bates ER, Lau WC, Angiolillo DJ. Clopidogrel–drug interactions. J Am Coll Cardiol 2011;15;57(11):1251-63.
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;22;360:(4)354-62.
Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;14;294(10):1224-32.
Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, et al. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J 2010;159(6):964-71.e1.
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and ASA followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358 (9281):527-33.
Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R,et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to ASA in 45 852 patients with acute myocardial infarction: a randomized placebo-controlled trial. Lancet 2005;366 (9497):1607-21.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to ASA in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345 (7):494-502.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus ASA in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;16;348(9038):1329-39.
Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Mosses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39 (1):9-14.
Santopinto J, Gurfinkel EP, Torres V, Marcos E, Bozovich GE, Mautner B, et al. Prior ASA users with acute non-STelevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 2001;141 (4):566-72.
Cohen M, Adams PC, McBride R, Blanke H, Fuster VV. Prospective comparison of patient characteristics and outcome of non-prior ASA users versus ASA users with unstable angina or non-Q-wave myocardial infarction treated with combination antithrombotic therapy. J Thromb Thrombolysis 1997;4 (2):275-80.
Garcia-Dorado D, Théroux P, Tornos P, Sambola A, Oliveras J, Santos M, et al. Previous aspirin use may attenuate the severity of the manifestations of acute ischemic syndromes. Circulation 1995;92 (7):1743-8.
Lancaster GI, Lancaster CJ, Radley D, Cohen M. Prior ASA use in unstable angina predisposes to the higher risk: the ASA paradox. Int J Cardiol 2001;80(2-3):201-7.
Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;27;113(25):2906–13.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent STsegment elevation of the European Society of Cardiology. Eur Heart J 2011;32(23):2999–3054.
Shankar H, Kahner B, Kunapuli SP. G-protein dependent platelet signaling-perspectives for therapy. Curr Drug Targets 2006;7(10):1253-63.
Dorsam RT, Kunapuli SP. Central role of the P2Y12receptor in platelet activation. J Clin Invest 2004;113(3):340-5.
Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;15;102(2):449-61.
Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003;1(7):1335-42.
Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003;1(7):1602-12.
Parveen June Kumar, Michael L. Clark (2005). "8". Clinical Medicine (6th ed.). Elsevier Saunders. p. 469. ISBN 0-7020-2763-4.